[Federal Register Volume 85, Number 56 (Monday, March 23, 2020)]
[Notices]
[Pages 16368-16369]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-06082]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2020-N-0008]


Blood Products Advisory Committee; Postponed

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The meeting of the Blood Products Advisory Committee (BPAC) 
scheduled for April 2-3, 2020, is postponed. The Food and Drug 
Administration (FDA), like other government agencies, is taking the 
necessary steps to ensure the Agency is prepared to continue our vital 
public health mission in the event that our day-to-day operations are 
impacted by the

[[Page 16369]]

COVID-19 public health emergency. Therefore, we are canceling or 
postponing all non-essential meetings through the month of April. We 
will reassess on an ongoing basis for future months. Therefore, this 
meeting is being postponed. The meeting was announced in the Federal 
Register on February 13, 2020.

FOR FURTHER INFORMATION CONTACT: Christina Vert, Center for Biologics 
Evaluation and Research, Food and Drug Administration, 10903 New 
Hampshire Ave., Bldg. 71, Rm. 6268, Silver Spring, MD 20993-0002, 240-
402-8054, [email protected], or FDA Advisory Committee 
Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC 
area), and follow the prompts to the desired center or product area. 
Please call the Information Line for up-to-date information on this 
meeting, which was announced in the Federal Register of February 13, 
2020, 85 FR 8299.

    Dated: March 18, 2020.
Lowell J. Schiller,
Principal Associate Commissioner for Policy.
[FR Doc. 2020-06082 Filed 3-20-20; 8:45 am]
 BILLING CODE 4164-01-P